Periodontitis and Cardiovascular Disease

The relationship between periodontitis and cardiovascular disease examines whether chronic periodontal inflammation is associated with, and might contribute to, atherosclerotic vascular disease such as coronary heart disease and stroke. Epidemiological studies consistently report a modest association, and inflammatory and microbial mechanisms make it biologically plausible, but whether the link is causal or reflects shared risk factors remains unresolved.

Definition

The periodontitis-cardiovascular disease relationship is the studied association between periodontitis and atherosclerotic cardiovascular disease, in which periodontal inflammation and oral bacteria are investigated as potential contributors to atherogenesis and vascular events.

Scope

This topic covers the observed epidemiological association between periodontitis and atherosclerotic cardiovascular disease, the proposed biological pathways, and the major consensus statements that have weighed the evidence. It deliberately separates a consistently reported association from a demonstrated causal effect and does not address management of cardiovascular risk in individuals, which is outside its scope.

Core questions

• Is the association between periodontitis and cardiovascular disease independent of shared risk factors such as smoking and age?
• What biological mechanisms could link periodontal infection to atherosclerosis?
• Does periodontal treatment alter cardiovascular risk markers, and does that translate to clinical outcomes?

Key concepts

• Atherosclerotic cardiovascular disease
• Systemic inflammation and C-reactive protein
• Bacteremia and endothelial effects
• Confounding by shared risk factors
• Independent association
• Surrogate markers versus hard outcomes

Mechanisms

Proposed pathways include direct and indirect mechanisms. Oral bacteria entering the circulation during chronic periodontal inflammation, and bacterial DNA detected in atherosclerotic plaques in some studies, suggest a possible direct contribution to vascular pathology. Indirectly, periodontitis raises systemic inflammatory markers and can affect endothelial function, both of which are relevant to atherogenesis. Hajishengallis and Chavakis (2021) frame these as part of a broader inflammatory link between periodontal disease and comorbidities. The American Heart Association statement (Lockhart et al., 2012) and the EFP/AAP and EFP consensus reports (Tonetti & Van Dyke, 2013; Sanz et al., 2020) judge the mechanisms plausible but emphasise that plausibility does not by itself establish causation.

Clinical relevance

This association is part of how periodontal and cardiovascular research communities understand the systemic context of oral inflammation, and it has motivated calls for awareness of oral health in cardiovascular research. At the level of an individual, the evidence summarised here describes a population association and does not establish that periodontal status should change cardiovascular diagnosis or treatment; it is presented as reference material, not clinical direction.

Epidemiology

Multiple observational studies and meta-analyses report that people with periodontitis have a modestly increased likelihood of atherosclerotic cardiovascular disease compared with those without, an association that tends to persist but attenuate after adjustment for shared risk factors. The American Heart Association reviewed this body of evidence and concluded that periodontal disease is associated with atherosclerotic vascular disease independent of known confounders, while noting that the data did not establish a causal relationship (Lockhart et al., 2012).

Evidence & guidelines

Two strands of consensus dominate this topic. The American Heart Association scientific statement (Lockhart et al., 2012) concluded that the association is supported but causation is unproven, and explicitly cautioned against statements implying that periodontal treatment prevents cardiovascular disease. The Joint EFP/AAP workshop (Tonetti & Van Dyke, 2013) and the subsequent EFP consensus report (Sanz et al., 2020) reached compatible conclusions, supporting an association and biological plausibility while identifying the lack of definitive intervention trials on hard cardiovascular outcomes as a key gap.

History

Reports associating poor oral health with cardiovascular disease appeared in the late twentieth century as part of the emerging field of periodontal medicine. As studies accumulated, professional bodies convened to appraise them: the American Heart Association issued a scientific statement in 2012, and the European and American periodontology federations addressed the question in joint and federation consensus reports in 2013 and 2020, progressively refining the conclusion that the association is real but its causal status uncertain.

Debates

Independent association versus residual confounding

Periodontitis and cardiovascular disease share strong risk factors, especially smoking, age, and socioeconomic status; debate continues over whether the association that remains after adjustment reflects a genuine independent link or residual and unmeasured confounding.

Does periodontal treatment reduce cardiovascular events?

Intervention studies show periodontal therapy can improve surrogate markers such as endothelial function and inflammatory markers, but no adequately powered trial has demonstrated a reduction in hard cardiovascular outcomes, leaving the clinical significance unresolved.

Key figures

• Peter Lockhart
• Maurizio Tonetti
• Mariano Sanz
• George Hajishengallis

Seminal works

• lockhart-2012
• tonetti-2013
• sanz-2020

Frequently asked questions

Does gum disease cause heart disease?

Studies consistently show an association between periodontitis and atherosclerotic cardiovascular disease, and the link is biologically plausible, but major consensus statements conclude that a causal effect has not been established and that shared risk factors may explain part of the association.

Will treating periodontitis lower my cardiovascular risk?

Periodontal treatment can improve some inflammatory and vascular markers in studies, but no large trial has shown that it reduces heart attacks or strokes, so this remains an open research question rather than an established clinical benefit.